Cell Therapy
25 videos · last 6 months shuffled daily, then older videos newest first
▶
10:12 How to Match CGT Manufacturing Models to Pipeline Needs
Omkar Kawalekar of Deloitte and Zoe Zheng of Legend Biotech on how early manufacturing decisions shape scalability, and the pitfall of treating manufacturing as a question about a facility.
▶
22:15 Delivering Advanced Neurotherapy Trials
Professor Liam Gray, director of the BRAIN Unit, and Professor Anne Rosser of Cardiff University discuss delivering trials of gene, RNA and cell therapies for Huntington's and Parkinson's diseases, for the Centre for Trials Research.
▶
1:41 Emerging Cellular Therapies in Gastrointestinal Cancers
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, discusses emerging cellular therapies in gastrointestinal (GI) cancer, including an engineered T-cell receptor therapy against p53 which has shown promise in pancreatic cancer and a CAR T-cell therapy targeting CLDN18.2.
▶
6:28 Revisiting CGT Manufacturing Strategy and De-Risking Tech Transfer
Omkar Kawalekar of Deloitte and Zoe Zheng of Legend Biotech on when cell and gene therapy developers should stress-test manufacturing strategy, arguing it starts in Phase 1 and is revisited as clinical data arrives.
▶
5:17 Kim Brown, CEO, Compass Biomedical
Kim Brown, CEO of Compass Biomedical, argues that the culture material cells are grown in quietly shapes the quality and consistency of the finished cell therapy product.
▶
4:02:40 Engaging Stakeholders in Cell and Gene Therapy Research
ASGCT and NORD host a workshop at the ASGCT 2026 Annual Meeting on engaging patients and other stakeholders in cell and gene therapy translational research.
▶
33:11 Multiple Sclerosis Breakthrough? Inside the Stem Cell Research That Could Transform MS Care
Dr. Flavia Nelson on regenerative stem cell therapy for aggressive, treatment-resistant multiple sclerosis, where the disease keeps progressing despite therapies that work for others.
▶
3:45:23 Cell and Gene Therapy Development: Regulatory Considerations
A Friends of Cancer Research meeting covers regulatory and operational considerations in cell therapy development, modernising early-phase clinical development, risk-based CMC flexibility and predictability in drug development policy.
▶
1:13:06 Parkinson's Disease Modification and Stem Cell Research
Michael S. Okun, MD, of the Norman Fixel Institute for Neurological Diseases reviews where Parkinson's disease-modifying research stands, including cell replacement therapies, disease-modifying trials and ethics, for the Parkinson's Foundation.
▶
16:22 CoRegen on Engineered Tregs for Solid Tumors
Sonal Gupta, MD, PhD, Chief Medical Officer of CoRegen, discusses the company's investigational engineered Treg cell therapy CRG150 for solid tumors, its move into first-in-human studies and CDMO selection, on Life Science Connect's Cell & Gene: The Podcast.
▶
50:30 Nkarta's Paul Hastings on Cell Therapy and Trial Access
Paul Hastings, Founding CEO of Nkarta, discusses off-the-shelf CAR NK cell therapies for autoimmune disease, problems with US clinical trial infrastructure and community health centers as new trial sites, on Life Science Connect's Business of Biotech.
▶
5:14 Dopamine Neuron Cell Replacement Therapy for Parkinson's Disease with Melita Petrossian, MD
Melita Petrossian, MD, on the trials now testing dopamine neuron cell replacement in Parkinson's disease, which loses the neurons that release dopamine to control movement.
▶
1:06:02 TIL Therapy for Melanoma: A Patient Perspective and What’s New in Research
The Melanoma Research Alliance on tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma — a patient's perspective, and what is new in the research.
▶
1:01:50 Deramiocel FDA Advisory Committee Town Hall
Parent Project Muscular Dystrophy and other Duchenne groups review the July 29, 2026 FDA advisory committee meeting on deramiocel, the committee's vote and what it means, and the steps leading to the FDA's August 22, 2026 action date.
▶
1:27:12 OTP Town Hall: Cell Therapy CMC Readiness for Late-Stage INDs
The FDA's Office of Therapeutic Products answers questions on chemistry, manufacturing and controls readiness for late-stage cell therapy INDs, in a September 2024 town hall.
▶
7:47 Supply Chain Orchestration, Priorities for Smaller CGT Biotechs
Omkar Kawalekar of Deloitte and Zoe Zheng of Legend Biotech on cell and gene therapy supply chains, and why the worst vulnerabilities show up in patient scheduling, data fragmentation and QC release.
▶
10:34 CGT Biotech/CDMO Transparency & Core Capabilities
Omkar Kawalekar of Deloitte and Zoe Zheng of Legend Biotech on what cell and gene therapy developers should look for in a CDMO partner: transparency, data visibility and capability rather than capacity.
▶
6:11 CGT Modality, Hybrid Models, And What To Keep In-House
Omkar Kawalekar of Deloitte and Zoe Zheng of Legend Biotech on how modality changes cell and gene therapy manufacturing, from patient-specific autologous programs to allogeneic and in vivo approaches.
▶
1:10:01 Expanding Access to Cell and Gene Therapies Across Africa
Speakers from Makerere University, Moi University and Benjamin Mkapa Hospital describe the regulatory, logistical and infrastructure challenges of establishing cell and gene therapy programmes in African countries, in an ASGCT webinar.
▶
22:11 CRO Parexel Discusses Challenges Working With New Therapies and New Regulations
CRO Parexel discusses the challenges a CRO faces including working of new therapies with a focus on oncology and cell therapies.
▶
53:53 Cellectis Clinical Pipeline Overview
Cellectis Chief Medical Officer Carrie Brownstein and Mark Frattini, SVP of Clinical and Translational Sciences, give an overview of the company's clinical product pipeline.
▶
7:25 Cell Therapy and Personalized Medicine From Cellares and AT&T
Start up Cellares develops modular factories to assist in the manufacture of cell therapies that can be used for personalized medicine.
▶
3:56 A Doctor’s Perspective on IN8bio’s Trial Results
Dr. Burt Nabors of UAB discusses IN8bio's gamma-delta T cell trial results in glioblastoma and how the approach differs from others.
▶
1:05:36 FDA Guidance for Cell and Gene Therapy: Insights from Peter Marks at CGT Summit 2023
In this keynote from the 2023 CGT Summit hosted by Charles River Laboratories, Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (CBER), shares his vision for the future of cell and gene therapy.